Pliant Therapeutics, Inc.
PLRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001746473
No open-market purchases or sales by Pliant Therapeutics, Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q2 2026, worth $54.8M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $48.7M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −4 vs. previous quarter
- 86
- 13F valueReported value at the end of Q2 2026
- $54.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $0
- No comparable prior period
- Net income, FY2025
- -$149.3M
- No comparable prior period
- Free cash flow, FY2025
- -$128.7M
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 4.88M
- Shares sold short
- Change
- +246.5K
- +5.3% vs. previous
- Days to cover
- 16.20
- At average daily volume
Superinvestors holding PLRX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding PLRX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Pliant Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 22, 2026 (view filing) | Jan 20 | 2 days | Cummings Keith LamontChief Financial Officer | SSale | −24.0K | $1.28 | −$30.7K | −7.5%297.2K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 20 | 2 days | Cheung LilyChief Human Resource Officer | SSale | −7.53K | $1.28 | −$9.64K | −14.4%44.8K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 20 | 2 days | Coulie BernardPresident and CEO | SSale | −89.4K | $1.28 | −$114.4K | −15.0%505.6K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 20 | 2 days | Kuo MinnieChief Operating Officer | SSale | −6.92K | $1.28 | −$8.85K | −15.5%37.8K after | 10b5-1 |
| Jan 22, 2025 (view filing) | Jan 17 | 5 days | Coulie BernardPresident and CEO | SSale | −52.4K | $11.20 | −$587.1K | −10.9%430.5K after | 10b5-1 |
| Jan 22, 2025 (view filing) | Jan 17 | 5 days | Cummings Keith LamontChief Financial Officer | SSale | −20.1K | $11.20 | −$225.7K | −7.1%262.6K after | 10b5-1 |
| Jan 22, 2025 (view filing) | Jan 17 | 5 days | Hull HansChief Business Officer | SSale | −15.9K | $11.20 | −$178.5K | −7.0%211.6K after | 10b5-1 |
| Jan 22, 2025 (view filing) | Jan 17 | 5 days | Lefebvre EricChief Medical Officer | SSale | −18.5K | $11.20 | −$207.0K | −8.7%194.6K after | 10b5-1 |
| Jan 22, 2025 (view filing) | Jan 17 | 5 days | Cheung LilyChief Human Resource Officer | SSale | −3.74K | $11.20 | −$41.9K | −13.2%24.6K after | 10b5-1 |
| Jan 22, 2025 (view filing) | Jan 17-22 | 5 days | Ouimette MikeGeneral Counsel & Corp. Sec'y | SSale | −23.5K | $11.11 | −$261.1K | −25.0%70.5K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 86 holdersThe largest institutional positions in Pliant Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 6,141,261 | $7.00M | 0.32% | −1,8710.0% | Reduced |
| ADAR1 Capital Management, LLC | 5,509,724 | $6.28M | 0.30% | +2,924,598+113.1% | Added |
| Vanguard Capital Management LLC | 2,440,351 | $2.78M | 0.00% | +97,250+4.2% | Added |
| Acadian Asset Management LLC | 2,416,508 | $2.75M | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 2,262,832 | $2.58M | 0.00% | +9,694+0.4% | Added |
| Citadel Advisors LLC | 2,142,226 | $2.44M | 0.00% | −1,084,373−33.6% | Reduced |
| Renaissance Technologies LLC | 2,049,874 | $2.34M | 0.00% | +197,032+10.6% | Added |
| Monaco Asset Management SAM | 1,938,747 | $2.21M | 0.82% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 1,798,070 | $2.05M | 0.24% | +1,798,070 | New |
| BML Capital Management, LLC | 1,546,137 | $1.76M | 1.01% | 00.0% | Unchanged |
Holders of 5% or more of PLRX
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Pliant Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Tang Capital Management LLC | 13D | 9.60%5.86M shares | New | Mar 10, 20251 filing | Mar 10, 2025 | SEC |
| ADAR1 Capital Management, LLC | 13G | 8.90%5.51M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |